about
MicroRNAs in B-cells: from normal differentiation to treatment of malignanciesDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine.Identifying microRNAs involved in aging of the lateral wall of the cochlear ductSynthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a ∼ 125b cluster function by seed-targeting inhibitors in multiple myeloma cellsPromises and challenges of MicroRNA-based treatment of multiple myelomaThe expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.The Role of miRNA in Haematological Malignancy.DNA methylation of microRNA genes in multiple myeloma.Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.MicroRNA theragnostics for the clinical management of multiple myeloma.The potential of miRNAs as biomarkers for multiple myeloma.Epigenetics in Multiple Myeloma.Identification of subtype specific miRNA-mRNA functional regulatory modules in matched miRNA-mRNA expression data: multiple myeloma as a case.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
P2860
Q26824682-A07B11D9-39C8-42DA-BDFE-EB266928902FQ27692033-A6F450FC-8490-4FC9-8E12-20D2B77FF5A2Q33741100-388DE4C5-1473-4FE5-9BA2-25184EFFDF25Q33852683-E8F738D9-582E-4CB4-B402-C5064A2CA1F0Q33896588-62E8EC48-6B10-4BD9-B8BB-CB18DF9BB753Q34535461-8B230071-0F34-4645-88C5-E0DE41E3C66CQ35678607-F41F9F9E-D5BA-441A-AC44-CA4F0DD907D6Q36189632-2F1A571F-1D9D-4AD5-BA07-D87AED22454FQ36419086-9EC5832E-17A1-471B-8923-E4F1D7C524BCQ36439245-1F8A30C9-759E-4F74-8ED5-880D90CB606EQ37422388-D995592E-45D5-4343-A903-AB0D08838641Q38020153-5091AADD-EC7A-4B3E-8EEE-C9EE6295C435Q38101343-850EB506-AAEF-470C-86E1-F1E9FE3F0C5AQ38190971-577EF3BC-48BC-4F06-9F97-9C5370618BD9Q38203140-3FEC411A-599E-4127-B8C1-B9BE9D4711D6Q38237446-6B09CC44-B953-42E9-A9FE-D0220997A747Q38970577-8C772AFF-96EE-48A4-B86B-D13B99C944B4Q41072852-E32AF573-35C8-411B-B455-49FCCA458B73Q41963512-AFD021C5-DD8D-48FA-809E-394CE98837DCQ48104779-95D79B15-4ED2-41B2-9D9F-85826A744AECQ48236958-73E00634-3920-4BA8-8549-8845851B531B
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
MicroRNAs: New Players in Multiple Myeloma.
@ast
MicroRNAs: New Players in Multiple Myeloma.
@en
type
label
MicroRNAs: New Players in Multiple Myeloma.
@ast
MicroRNAs: New Players in Multiple Myeloma.
@en
prefLabel
MicroRNAs: New Players in Multiple Myeloma.
@ast
MicroRNAs: New Players in Multiple Myeloma.
@en
P2860
P356
P1476
MicroRNAs: New Players in Multiple Myeloma.
@en
P2093
Flavia Pichiorri
Rami I Aqeilan
P2860
P356
10.3389/FGENE.2011.00022
P577
2011-05-24T00:00:00Z